Clinical review report: Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi) (Gilead Sciences Canada, Inc.)
The objective of this report was to perform a systematic review of the beneficial and harmful effects of a Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) (400 mg / 100 mg / 100 mg) single-tablet regimen for the treatment of chronic hepatitis C (CHC) genotype 1, 2, 3, 4, 5, and 6 infection in adul...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2018, February 2018
|
| Edition: | Version: final |
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of this report was to perform a systematic review of the beneficial and harmful effects of a Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) (400 mg / 100 mg / 100 mg) single-tablet regimen for the treatment of chronic hepatitis C (CHC) genotype 1, 2, 3, 4, 5, and 6 infection in adults who are direct-acting antiviral agent (DAA) treatment experienced |
|---|---|
| Item Description: | "Indication: Hepatitis C infection genotype 1 to 6." |
| Physical Description: | 1 PDF file (66 pages) illustrations |